Tweet
Nat Rev Immunol
. 2022 Sep 27.
doi: 10.1038/s41577-022-00784-3. Online ahead of print.
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
Yanjia Chen # 1 , Xiaoyu Zhao # 1 , Hao Zhou # 2 3 , Huanzhang Zhu 1 , Shibo Jiang 4 , Pengfei Wang 5
Affiliations
- PMID: 36168054
- DOI: 10.1038/s41577-022-00784-3
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus Betacoronavirus. The ancestor strain has evolved into a number of variants of concern, with the Omicron variant of concern now having many distinct sublineages. The ongoing COVID-19 pandemic caused by SARS-CoV-2 has caused serious damage to public health and the global economy, and one strategy to combat COVID-19 has been the development of broadly neutralizing antibodies for prophylactic and therapeutic use. Many are in preclinical and clinical development, and a few have been approved for emergency use. Here we summarize neutralizing antibodies that target four key regions within the SARS-CoV-2 spike (S) protein, namely the N-terminal domain and the receptor-binding domain in the S1 subunit, and the stem helix region and the fusion peptide region in the S2 subunit. Understanding the characteristics of these broadly neutralizing antibodies will accelerate the development of new antibody therapeutics and provide guidance for the rational design of next-generation vaccines.